Advertisement

Assessing the Importance of Factors Associated with Cost-Related Nonadherence to Medication for Older US Medicare Beneficiaries

  • Dian GuEmail author
  • Chan Shen
Original Research Article
  • 19 Downloads

Abstract

Background

Prescription drug costs have been rising rapidly in the USA, contributing to the persistent problem of cost-related medication nonadherence (CRN) among older Medicare beneficiaries. Given the importance of CRN and the negative outcomes associated with it, it is important to examine the factors that affect CRN. This study aims to estimate the factors influencing CRN among older Medicare beneficiaries and to rank their relative contribution in explaining CRN.

Methods

We used a 2015 Medicare Current Beneficiary Survey linked to Medicare claims data to identify older Medicare beneficiaries aged 65 years and over. Multivariate logistic regression was performed to identify factors associated with CRN. Factors included in the regression analyses were based on a conceptual framework adapted from Piette et al., including main effects (financial factors and regimen complexity) and contextual factors (sociodemographic, lifestyle and health factors). Dominance analysis was conducted to determine their relative importance in predicting CRN.

Results

Our study sample included 4427 older Medicare beneficiaries, 13.43% of whom reported CRN. For main effects, drug coverage and regimen complexity were significantly associated with CRN. Compared to beneficiaries with public coverage, those with private drug coverage were less likely to report CRN while those without drug coverage were more likely to report CRN. Having more than two monthly prescriptions was also associated with higher CRN. Significant contextual factors included age, activities of daily living limitations, perceived health status, cancer, rheumatoid arthritis, non-rheumatoid arthritis, depression, and lung disease. Dominance analysis showed drug coverage was the most influential factor in explaining CRN, after which age, ADL limitations, and depression ranked in sequence.

Conclusions

These findings can help policy makers understand the relative importance of factors affecting CRN and identify the most important areas for intervention to improve CRN.

Notes

Acknowledgements

We thank Gary Deyter for his editorial assistance.

Author Contributions

All authors contributed to the planning, conduct, and reporting of the work described in the article. Dian Gu is responsible for the overall content as the guarantor.

Compliance with Ethical Standards

Funding

No funding was received for the conduct of this study or the preparation of this article.

Conflict of interest

Dian Gu and Chan Shen have no conflicts of interest that are directly relevant to the content of this article.

Ethics Approval

This study received institutional review board exemption status from the University of Texas MD Anderson Cancer Center.

References

  1. 1.
    He W, Goodkind D, Kowal PR. An aging world: 2015. Washington, DC: United States Census Bureau; 2016.Google Scholar
  2. 2.
    Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidities. 2011;1:28–44.CrossRefGoogle Scholar
  3. 3.
    Schumock GT, Stubbings J, Wiest MD, Li EC, Suda KJ, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2018. Am J Health Syst Pharm. 2018;75:1023–38.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858–71.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Madden JM, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008;299:1922–8.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically III adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94:1782–7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626–34.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Zivin K, Ratliff S, Heisler MM, Langa KM, Piette JD. Factors influencing cost-related nonadherence to medication in older adults: a conceptually based approach. Value Health. 2010;13:338–45.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Piette JD, Heisler M, Horne R, Alexander GC. A conceptually based approach to understanding chronically ill patients’ responses to medication cost pressures. Soc Sci Med. 2006;62:846–57.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22:864–71.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Zhang JX, Lee JU, Meltzer DO. Risk factors for cost-related medication non-adherence among older patients with diabetes. World J Diabetes. 2014;5:945–50.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Zhang JX, Meltzer DO. Risk factors for cost-related medication non-adherence among older patients with cancer. Integr Cancer Sci Ther. 2015;2:300–4.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Blumberg DM, Prager AJ, Liebmann JM, Cioffi GA, De Moraes CG. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of Medicare Part D. JAMA Ophthalmol. 2015;133:985–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013;40:137–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Kang H, Lobo JM, Kim S, Sohn M-W. Cost-related medication non-adherence among US adults with diabetes. Diabetes Res Clin Pract. 2018;143:24–33.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31:2398–403.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Centers for Medicare and Medicaid Service. Medicare Current Beneficiary Survey related files. https://www.cms.gov/MCBS. Accessed Dec 2018.
  19. 19.
    Burcu M, Alexander GC, Ng X, Harrington D. Construct validity and factor structure of survey-based assessment of cost-related medication burden. Med Care. 2015;53:199–206.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Piette JD, Beard A, Rosland AM, McHorney CA. Beliefs that influence cost-related medication non-adherence among the “haves” and “have nots” with chronic diseases. Patient Pref Adherence. 2011;5:389–96.CrossRefGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention. About adult BMI. http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html. Accessed Dec 2018.
  22. 22.
    Bambauer KZ, Safran DG, Ross-Degnan D, Zhang F, Adams AS, Gurwitz J, et al. Depression and cost-related medication nonadherence in Medicare beneficiaries. Arch Gen Psychiatry. 2007;64:602–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Zivin K, Madden JM, Zhang F, Soumerai SB, Graves AJ. Cost-related medication nonadherence among beneficiaries with depression following Medicare Part D. Am J Geriatr Psychiatry. 2009;17:1068–76.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Rogers WH, Wilson IB, Bungay KM, Cynn DJ, Adler DA. Assessing the performance of a new depression screener for primary care (PC-SAD). J Clin Epidemiol. 2002;55:164–75.PubMedCrossRefGoogle Scholar
  25. 25.
    Rogers WH, Adler DA, Bungay KM, Wilson IB. Depression screening instruments made good severity measures in a cross-sectional analysis. J Clin Epidemiol. 2005;58:370–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods. 2003;8:129–48.PubMedCrossRefGoogle Scholar
  27. 27.
    Azen R, Traxel N. Using dominance analysis to determine predictor importance in logistic regression. J Educ Behav Stat. 2009;34:319–47.CrossRefGoogle Scholar
  28. 28.
    Grömping U. Estimators of relative importance in linear regression based on variance decomposition. Am Statistician. 2007;261:139–47.CrossRefGoogle Scholar
  29. 29.
    Luchman JN. Determining subgroup difference importance with complex survey designs: an application of weighted dominance analysis. Surv Pract. 2015;8:1–10.CrossRefGoogle Scholar
  30. 30.
    Soumerai SB, Pierre-Jacques M, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, et al. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med. 2006;166:1829–35.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Kaiser Family Foundation. How does prescription drug spending and use compare across large employer plans, Medicare Part D, and Medicaid? https://www.kff.org/medicare/issue-brief/how-does-prescription-drug-spending-and-use-compare-across-large-employer-plans-medicare-part-d-and medicaid/. Accessed May 2019.
  32. 32.
    Gellad WF, Grenard J, McGlynn EA, Gellad WF, Grenard JL, McGlynn EA. A review of barriers to medication adherence. In: A framework for driving policy options. Santa Monica, CA: RAND Corp; 2009.Google Scholar
  33. 33.
    Aziz H, Hatah E, Bakry MM, et al. How payment scheme affects patients’ adherence to medications? A systematic review. Patient Prefer Adherence. 2016;10:837–50.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Cohen MJ, Shaykevich S, Cawthon C, Kripalani S, Paasche-Orlow MK, Schnipper JL. Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence. J Hosp Med. 2012;7:470–5.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Gazmararian J, Jacobson KL, Pan Y, Schmotzer B, Kripalani S. Effect of a pharmacy-based health literacy intervention and patient characteristics on medication refill adherence in an urban health system. Ann Pharmacother. 2010;44:80–7.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl. 1):S19–25.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Zhang JX, Lee JU, Pandey K, Meltzer DO. Variation in cost-related medication non-adherence with functional limitations and frequency of hospitalization in older adults. Ann Gerontol Geriatric Res. 2015;2(1):1023.Google Scholar
  38. 38.
    Chan L, Beaver S, MacLehose RF, Jha A, Maciejewski M, Doctor JN. Disability and health care costs in the Medicare population. Arch Phys Med Rehab. 2002;83:1196–201.CrossRefGoogle Scholar
  39. 39.
    MacLachlan M, Mannan H, McAuliffe E. Access to health care of persons with disabilities as an indicator of equity in health systems. Open Med. 2011;5:e10.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Pellegrino LD, Peters ME, Lyketsos CG, Marano CM. Depression in cognitive impairment. Curr Psychiatry Rep. 2013;15:384.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Campbell NL, Boustani MA, Skopelja EN, Gao S, Unverzagt FW, Murray MD. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother. 2012;10:165–77.PubMedCrossRefGoogle Scholar
  42. 42.
    Nekhlyudov L, Madden J, Graves AJ, Zhang F, Soumerai SB, Ross-Degnan D. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv. 2011;5:395–404.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018;6(9):166.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Peppercorn J. Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions. Oncologist. 2017;22(2):123–5.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Aikens JE, Piette JD. Diabetic patients’ medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. Diabetes Care. 2009;32:19–24.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Piette JD, Heisler M, Wagner TH. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy in response to financial pressures. J Clin Epidemiol. 2006;59:739–46.PubMedCrossRefGoogle Scholar
  47. 47.
    Yap AF, Thirumoorthy T, Kwan YH. Medication adherence in the elderly. J Clin Gerontol Geriatr. 2016;7:64–7.CrossRefGoogle Scholar
  48. 48.
    Chang-Quan H, Bi-Rong D, Zhen-Chan L, Yuan Z, Yu-Sheng P, Qing-Xiu L. Collaborative care interventions for depression in the elderly: a systematic review of randomized controlled trials. J Investig Med. 2009;57:446–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Health Services ResearchThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Division of Outcomes Research and Quality, Department of Surgery, College of MedicinePenn State UniversityHersheyUSA

Personalised recommendations